Cizzle Biotechnology Holdings plc is thrilled to announce a strategic agreement with BBI Solutions to supply its first order of commercial proprietary monoclonal antibodies. This partnership marks a significant milestone in Cizzle’s mission to commercialize its cost-effective biomarker test for early-stage lung cancer detection.
Home » News
July 22, 2024